A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepat
A phase 2 trial of Durvalumab, Bevacizumab in hepatocellular carcinoma, run by AstraZeneca, active and no longer recruiting.
Overview
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE is a phase 2 interventional study registered as NCT06040099 by AstraZeneca, with 58 participants enrolled, started 2024-02-13 and due to reach its primary completion in 2026-07-01. Interventions recorded: Durvalumab, Bevacizumab, Transarterial Radioembolization (TARE). Conditions listed: Hepatocellular Carcinoma (HCC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialAssess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
Shares Durvalumab, Bevacizumab, AstraZeneca, Hepatocellular carcinoma.
- TrialA Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
Shares Durvalumab, Bevacizumab, AstraZeneca, Hepatocellular carcinoma.
- TrialDurvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC
Shares Durvalumab, AstraZeneca, Hepatocellular carcinoma.
- TrialDurvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
Shares Durvalumab, AstraZeneca, Hepatocellular carcinoma.
- TrialA Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
Shares Durvalumab, AstraZeneca.
- TrialStudy of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Shares Durvalumab, Bevacizumab, Hepatocellular carcinoma.
- TrialDurvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
Shares Durvalumab, AstraZeneca, Hepatocellular carcinoma.
- TrialDurvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.
Shares Durvalumab, AstraZeneca.